Home Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
 

Keywords :   


Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials

2014-04-30 07:12:40| drugdiscoveryonline News Articles

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced today that GBR 900, a novel monoclonal antibody is entering human trials

Tags: human treatment pain entering

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.06Atlantic Tropical Weather Outlook
02.06Eastern North Pacific Tropical Weather Outlook
02.06Shops rush for Christmas stock as shipping costs surge
02.06Successful entrepreneurs dont worry about being different
02.06Eastern North Pacific Tropical Weather Outlook
02.06Atlantic Tropical Weather Outlook
01.06Mining for Pearlizing Agent 
01.06The Power of Zinc Pyrithione
More »